Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) are leading causes of vision loss, and are the leading cause of blindness for working age adults. Chronic hyperglycemia triggers a cascade of retinal changes, from microaneurysms and hemorrhages in its early stages to abnormal blood vessel growth, bleeding, and scar tissue formation in its advanced stages.

At PharmaLegacy, we offer a range of in vivo models designed to mimic the key aspects of human diabetic retinopathy. Our models, including the STZ-induced Diabetic Retinopathy model, provide a robust platform for evaluating the efficacy of your novel therapies, providing coverage of the entire range of disease progression and complications such as retinal neovascularization. With diabetic retinopathy models in mice, rats, rabbits, and non-human primates (NHP), PharmaLegacy can meet almost any preclinical need. We offer a full spectrum of services, from diverse drug administration routes to advanced ophthalmic examinations (OCT, FFA, f-ERG) and ex vivo analysis, all within our AAALAC-accredited facilities which have supported hundreds of successful IND filings. Partner with us to gain actionable insights, accelerate your pipeline, and bring new hope to the millions of patients battling diabetic retinopathy.